Table 1 Demographic, clinicopathologic and treatment features of breast cancer patients by molecular subtypes
From: Long-term outcomes of non-metastatic breast cancer patients by molecular subtypes
Variables | N (%) n = 1287 (100%) | Subtype | p-value | |||
|---|---|---|---|---|---|---|
HR+/Her2 n = 261 (20.3%) | HR+/Her2− n = 658 (51.1%) | HR−/Her2 + n = 163 (12.7%) | HR−/Her2− n = 205 (15.9%) | |||
Age | ||||||
< 50 | 799 (62.1) | 165 (63.2) | 406 (61.7) | 93 (57.1) | 135 (65.9) | 0.366 |
≥ 50 | 488 (37.9) | 96 (36.8) | 252 (38.3) | 70 (42.9) | 70 (34.1) | |
BMI | ||||||
< 30 | 898 (69.8) | 195 (74.7) | 448 (68.1) | 110 (67.5) | 145 (70.7) | 0.221 |
≥ 30 | 389 (30.2) | 66 (25.3) | 210 (31.9) | 53 (32.5) | 60 (29.3) | |
Education level | ||||||
< Diploma | 610 (47.4) | 109 (41.8) | 319 (48.5) | 75 (46.0) | 107 (52.2) | 0.130 |
≥ Diploma | 677 (52.6) | 152 (58.2) | 339 (51.5) | 88 (54.0) | 98 (47.8) | |
Marital status | ||||||
Single | 240 (18.6) | 49 (18.8) | 121 (18.4) | 36 (22.1) | 34 (16.6) | 0.598 |
Married | 1047 (81.4) | 212 (81.2) | 537 (81.6) | 127 (77.9) | 171 (83.4) | |
Family history of cancer | ||||||
No | 1114 (86.6) | 233 (89.3) | 564 (85.7) | 145 (89.0) | 172 (83.9) | 0.250 |
Yes | 173 (13.4) | 28 (10.7) | 94 (14.3) | 18 (11.0) | 33 (16.1) | |
Menopausal status | ||||||
Premenopausal | 836 (65.0) | 172 (65.9) | 432 (65.7) | 92 (56.4) | 140 (68.3) | 0.092 |
Postmenopausal | 451 (35.0) | 89 (34.1) | 226 (34.3) | 71 (43.6) | 65 (31.7) | |
Pathology | ||||||
Others | 149 (11.6) | 24 (9.2) | 78 (11.9) | 23 (14.1) | 24 (11.7) | 0.472 |
IDC | 1138 (88.4) | 237 (90.8) | 580 (88.1) | 140 (85.9) | 181 (88.3) | |
Tumor size (cm) | ||||||
< 2 | 302 (23.5) | 51 (19.5) | 180 (27.4) | 31 (19.0) | 40 (19.5) | 0.001 |
2–5 | 696 (54.1) | 147 (56.3) | 355 (54.0) | 78 (47.9) | 116 (56.6) | |
> 5 | 289 (22.5) | 63 (24.1) | 123 (18.7) | 54 (33.1) | 49 (23.9) | |
Histological grade differentiate | ||||||
Well | 151 (11.7) | 28 (10.7) | 109 (16.6) | 5 (3.1) | 11 (5.4) | < 0.001 |
Moderate | 779 (60.5) | 159 (60.9) | 423 (64.3) | 88 (54.0) | 107 (52.2) | |
Poor | 300 (23.3) | 59 (22.6) | 99 (15.0) | 63 (38.7) | 79 (38.5) | |
Unknown | 57 (4.4) | 15 (5.7) | 27 (4.1) | 7 (4.3) | 8 (3.9) | |
Stage | ||||||
I | 195 (15.2) | 31 (11.9) | 114 (17.3) | 17 (10.4) | 33 (16.1) | 0.038 |
II | 681 (52.9) | 135 (51.7) | 351 (53.3) | 82 (50.3) | 113 (55.1) | |
III | 411 (31.9) | 95 (36.4) | 193 (29.3) | 64 (39.3) | 59 (28.8) | |
Lymph node metastasis | ||||||
No | 468 (36.4) | 80 (30.7) | 244 (37.1) | 43 (26.4) | 101 (49.3) | < 0.001 |
Yes | 819 (63.6) | 181 (69.3) | 414 (62.9) | 120 (73.6) | 104 (50.7) | |
Type of surgery | ||||||
MRM | 658 (51.1) | 138 (52.9) | 329 (50.0) | 104 (63.8) | 87 (42.4) | 0.001 |
BCS | 629 (48.9) | 123 (47.1) | 329 (50.0) | 59 (36.2) | 118 (57.6) | |
Hormone therapy* | ||||||
No | 203 (15.8) | 5 (1.9) | 7 (1.1) | 86 (52.8) | 105 (51.2) | < 0.001 |
Yes | 1033 (80.3) | 256 (98.1) | 651 (98.9) | 63 (38.7) | 63 (30.7) | |
Unknown | 51 (4.0) | 0 (0.0) | 0 (0.0) | 14 (8.6) | 37 (18.0) | |
Radiotherapy | ||||||
No | 126 (9.8) | 28 (10.7) | 65 (9.9) | 15 (9.2) | 18 (8.8) | 0.904 |
Yes | 1161 (90.2) | 233 (89.3) | 593 (90.1) | 148 (90.8) | 187 (91.2) | |
Adjuvant chemotherapy | ||||||
No | 267 (20.7) | 63 (24.1) | 117 (17.8) | 44 (27.0) | 43 (21.0) | 0.022 |
Yes | 941 (73.1) | 184 (70.5) | 490 (74.5) | 112 (68.7) | 155 (75.6) | |
Unknown | 79 (6.1) | 14 (5.4) | 51 (7.8) | 7 (4.3) | 7 (3.4) | |
Recurrence | ||||||
No | 1226 (95.3) | 250 (95.8) | 638 (97.0) | 144 (88.3) | 194 (94.6) | < 0.001 |
Yes | 61 (4.7) | 11 (4.2) | 20 (3.0) | 19 (11.7) | 11 (5.4) | |
Metastasis | ||||||
No | 1149 (89.3) | 234 (89.7) | 596 (90.6) | 137 (84.0) | 182 (88.8) | 0.116 |
Yes | 138 (10.7) | 27 (10.3) | 62 (9.4) | 26 (16.0) | 23 (11.2) | |
Death | ||||||
No | 1087 (84.5) | 224 (85.8) | 569 (86.5) | 122 (74.8) | 172 (83.9) | 0.003 |
Yes | 200(15.5) | 37(14.2) | 89(13.5) | 41(25.2) | 33(16.1) | |